In anticipation of its presentation at the 43rd Annual J.P. Morgan Healthcare Conference, Moderna, Inc. (MRNA) has reported achieving between $3.0 billion and $3.1 billion in product sales, while successfully reducing cash operating expenses by over 25% compared to 2023. The company is targeting a further reduction in cash costs by $1 billion in 2025 and an additional $500 million in savings by 2026.
Moderna is entering 2025 with a strategic focus on a prioritized portfolio that addresses significant medical areas such as respiratory viruses, rare diseases, oncology, and latent viruses where there is currently an unmet need.
For the year 2025, Moderna forecasts revenues in the range of $1.5 billion to $2.5 billion, with a substantial portion expected in the latter half of the year, driven primarily by its product Spikevax.
Additionally, the company anticipates achieving significant milestones across 10 key programs, which include the potential approval of up to three products by 2025, along with six data readouts that could lead to registration.
The material has been provided by InstaForex Company - www.instaforex.com
RobotFX
Posts
Posts
No comments:
Post a Comment